Furthermore, recent first-line studies of pembrolizumab, in combination with platinum doublets in metastatic non-squamous and squamous NSCLC, benefited from the addition of ICIs to chemotherapy irrespective of PD-L1 expression [11,12,13,14]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.